New Universal Cancer Medication Invention Blood Cell 1V1
Why Blood Cell 1V1 is Different
- Universal Strategy – Targets all cancer types and stages.
- Novel Mechanism – Works differently from chemo, radio, or immunotherapy.
- No Surgery Required – Potential treatment without invasive operations.
- Fewer Side Effects – Protects healthy cells.
- Higher Survival Potential – Promising for longer lives.
- Accessible for All – Developed under a CIC, not for profit.
- Globally Scalable – Suitable even in low-resource settings.
Patent Pending with UK IPO: GP2514353.8 London England
Our invention, Blood Cell 1V1, has been officially filed with the UK Intellectual Property Office under patent application number GB2514353.8. This demonstrates our legal protection and commitment to advancing innovative medical solutions. We are now seeking funding to support pre-clinical and clinical trials.
Every day matters – your support today helps us move one step closer to saving millions of lives.
Global Project to Fund Early Stages and Clinical Trials
A New Hope in the Fight Against Cancer
Cancer continues to be one of humanity’s greatest challenges, taking millions of lives every year and causing immeasurable suffering for families across the globe. Despite enormous progress in medical science, there remains an urgent need for new, more effective, and more accessible treatments.
Option 2 : Donate by Direct Bank Transfer
Funding Goal
We aim to raise Many million of USD to begin work on the first two critical stages of development:
- Research & Development (R&D) – invention design, hypotheses, computer modelling, and proof-of-concept experiments.
- GLP Toxicology Studies (Safety Testing) – mandatory safety testing to determine potential risks and prepare for regulatory approval.
Securing this initial funding will allow us to progress rapidly from concept to validated pre-clinical data, paving the way toward clinical trials.
Why This Project Matters
• Global Impact: Cancer affects every country, every community, and every family. Blood Cell 1V1 has been designed as a universal treatment strategy, not limited by region, age, or cancer type.
• Scientific Innovation: This medication introduces a novel mechanism that could provide greater effectiveness, fewer side effects, and higher survival rates compared to existing treatments.
• Community-Driven Approach: Unlike profit-driven pharmaceutical models, our project is being advanced under a Community Interest Company (CIC) structure, ensuring that funding is used for the public good.
This is not just another drug development program. It is a global humanitarian mission to bring life-saving innovation to those who need it most.
Blood Cell 1V1 – Development Pathway & Total Cost Estimate
1. Research & Development (R&D)
Current Stage – where we are now
- Activities:
- Invention design
- Lab hypotheses / computer modelling
- Early non-GLP experiments (proof of concept)
- Goal: Demonstrate that Blood Cell 1V1 has strong scientific potential.
Estimated Cost: Many Million USD
2. GLP Toxicology Studies (Safety Testing)
- Mandatory GLOP-compliant animal safety studies.
- Questions answered:
- Does Blood Cell 1V1 cause harm?
- At what dose?
- Which organs are affected?
- Essential for human testing approval.
Estimated Cost:Many Million USD
3. IND Submission (Investigation al New Drug Application)
- Regulatory submission to FDA (USA), EMA (EU), or MHRA (UK).
- Content includes:
- All R&D data
- GLP toxicology results
- Manufacturing (CMC – Chemistry, Manufacturing, Controls)
- Clinical trial design (Phase 1)
- Goal: Secure approval to begin clinical trials.
Estimated Cost: Several million + regulatory fees USD
4. Clinical Trials (Phases 1–3)
- Phase 1 (Safety & Dosage)
- 20–100 participants
- Safety profile, tolerability, dosing
- Cost Many Million USD
- Phase 2 (Efficacy & Side Effects)
- Cost: Many Million USD
- Proof of efficacy, monitoring side effects
- Cost: Many Million USD
- Phase 3 (Large-Scale Efficacy & Safety)
- 1,000–3,000 patients, often multi-country
- Definitive proof for regulators
- Cost: Many Million USD
5. Regulatory Approval (NDA/BLA Filing)
- NDA = New Drug Application (small molecules)
- BLA = Biologics License Application (for platforms like Blood Cell 1V1)
- Submission to FDA/EMA for marketing authorization.
Total Development Cost
- Estimated Many billion of USD if conducted with a single high-tech laboratory.
To accelerate development and achieve results within a few years instead of decades, our strategy is to:
- Partner with three high-tech laboratories at three leading global universities.
- Assign one part of Blood Cell 1V1 to each laboratory.
- Run parallel research and development streams, drastically reducing the overall timeline to reach clinical stages.
How Your Support Will Be Used
Developing a new cancer medication is a complex, multi-stage process requiring significant investment. Through this global project, we aim to raise funding to cover the early development stages and clinical trials in partnership with world-class universities such as Oxford, Cambridge, and UCL.
Your contribution will directly support:
1. Pre-Clinical Research – laboratory studies to confirm safety and effectiveness.
2. Clinical Trials (Phases I–III) – ensuring the medication is safe for humans, effective against cancer, and ready for regulatory approval.
3. Expert Teams – world-leading scientists, medical researchers, and clinicians working under strict international standards.
4. Transparency & Governance – all funds are managed by the CIC with a transparent 15% overhead policy, covering legal, accounting, compliance, travel, and essential staff salaries, ensuring that at least 85% goes directly into research and trials.
Why Fund Through a CIC?
A Community Interest Company is legally structured to serve the public, not private shareholders. This ensures that:
• Every donation or investment is used for community benefit, not excessive profit.
• Annual reports guarantee full accountability and transparency.
• Funders gain confidence that their contribution directly fuels the mission of defeating cancer.
This structure makes Blood Cell 1V1 one of the most credible, trustworthy, and funder-friendly projects in the field of global health innovation.
Join Us in Making History
By supporting Blood Cell 1V1, you are not only funding a new medication — you are helping to write a new chapter in the global fight against cancer.
We invite:
• Governments to partner with us in pioneering a new model of public–private collaboration.
• Foundations and Philanthropists to fund a project that will leave a legacy of hope for generations.
• Businesses and Corporations to align with a medical breakthrough that shows commitment to global well-being.
• Individuals to donate and be part of a worldwide movement to save lives.
The Call to Action
Every day matters. Every donation, every grant, and every partnership brings us one step closer to transforming Blood Cell 1V1 from a protected idea into a life-saving reality.
Together, we can bring this revolutionary cancer treatment to the world. Together, we can save millions of lives.
Be part of the cure. Join us in funding the future of cancer medicine.
NOTE: The inventor is currently unable to attend in-person meetings due to a busy research and development schedule. For secure communication, please contact him directly via
WhatsApp +447485234109
or by email at: global.services@gmtorg.com
Blood Cell 1V1 – A Global Project to Fund Early Stages and Clinical Trials
Patent Pending (UKIPO: GP2514353.8) | Managed by Blood Cell 1V1 CIC
Inventions Global 